AptarGroup, Inc. logo

AptarGroup, Inc. (ATR)

Market Closed
3 Jul, 20:00
NYSE NYSE
$
161. 04
+0.72
+0.45%
$
10.29B Market Cap
31.31 P/E Ratio
1.8% Div Yield
235,100 Volume
4.69 Eps
$ 160.32
Previous Close
Day Range
159.82 161.36
Year Range
130.85 178.03
Want to track ATR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 18 days

Summary

ATR closed yesterday higher at $161.04, an increase of 0.45% from Wednesday's close, completing a monthly increase of 2.22% or $3.5. Over the past 12 months, ATR stock gained 2.15%.
ATR pays dividends to its shareholders, with the most recent payment made on May 22, 2025. The next estimated payment will be in In 1 month on Aug 22, 2025 for a total of $0.45.
The last earnings report, released on Apr 23, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.11%, based on the last three reports. The next scheduled earnings report is due on Jul 23, 2025.
AptarGroup, Inc. has completed 2 stock splits, with the recent split occurring on May 10, 2007.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NYSE (USD).

ATR Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

PRINCETON, N.J. , July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorbâ„¢-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.

Prnewswire | 3 days ago
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorbâ„¢-ATR

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorbâ„¢-ATR

PRINCETON, N.J. , June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device,  (the denial letter).

Prnewswire | 1 week ago
AptarGroup (ATR) Upgraded to Strong Buy: Here's Why

AptarGroup (ATR) Upgraded to Strong Buy: Here's Why

AptarGroup (ATR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 2 weeks ago

AptarGroup, Inc. Dividends

AptarGroup, Inc. logo
ATR In 3 weeks
Estimated
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 2 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 5 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 8 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 11 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 24 Apr 2024
Paid
Quarterly
$0.41 Per Share

AptarGroup, Inc. Earnings

23 Jul 2025 (In 2 weeks) Date
1.57
Cons. EPS
-
EPS
23 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
1.26
Cons. EPS
1.52
EPS
24 Oct 2024 Date
1.42
Cons. EPS
1.49
EPS
25 Jul 2024 Date
1.36
Cons. EPS
1.37
EPS
AptarGroup, Inc. logo
ATR In 3 weeks
Estimated
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 2 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 5 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 8 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 11 months ago
Paid
Quarterly
$0.45 Per Share
AptarGroup, Inc. logo
ATR 24 Apr 2024
Paid
Quarterly
$0.41 Per Share
23 Jul 2025 (In 2 weeks) Date
1.57
Cons. EPS
-
EPS
23 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
1.26
Cons. EPS
1.52
EPS
24 Oct 2024 Date
1.42
Cons. EPS
1.49
EPS
25 Jul 2024 Date
1.36
Cons. EPS
1.37
EPS

AptarGroup, Inc. (ATR) FAQ

What is the stock price today?

The current price is $161.04.

On which exchange is it traded?

AptarGroup, Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is ATR.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.8%.

What is its market cap?

As of today, the market cap is 10.29B.

What is the earnings per share?

The EPS is 1.57.

When is the next earnings date?

The next earnings report will release on Jul 23, 2025.

Has AptarGroup, Inc. ever had a stock split?

AptarGroup, Inc. had 2 splits and the recent split was on May 10, 2007.

AptarGroup, Inc. Profile

Medical - Instruments & Supplies Industry
Healthcare Sector
Stephan B. Tanda CEO
NYSE Exchange
038336103 Cusip
US Country
13,000 Employees
5 Feb 2025 Last Dividend
10 May 2007 Last Split
21 Apr 1993 IPO Date

Overview

AptarGroup, Inc. is at the forefront of designing and manufacturing innovative solutions for drug delivery, consumer product dispensing, and active material science. With a diverse portfolio aimed at meeting the needs of various markets such as pharmaceuticals, beauty, personal care, home care, and food and beverage, AptarGroup emphasizes its commitment to addressing consumer demands and industry challenges. Operating through three primary segments - Aptar Pharma, Aptar Beauty, and Aptar Closures, the company showcases a multifaceted approach to delivering excellence and innovation. Since its incorporation in 1992, AptarGroup has established a significant global presence, actively serving customers across Asia, Europe, Latin America, and North America from its headquarters in Crystal Lake, Illinois. This extensive footprint underscores its dedication to accessibility and service excellence worldwide.

Products and Services

The comprehensive range of products and services offered by AptarGroup caters to a wide array of market needs, ensuring high-quality, innovative solutions that enhance user experience and functionality. Here's a closer look at their offerings:

  • Pumps for Nasal Allergy Treatments: AptarGroup has developed specialized dispensing pumps designed for the efficient and effective delivery of medication for nasal allergy relief. These products emphasize precision, ease of use, and improved patient compliance.
  • Metered Dose Inhaler Valves: Targeted towards individuals with respiratory ailments such as asthma and chronic obstructive pulmonary diseases (COPD), these valves are a critical component in metered dose inhalers, facilitating accurate medication delivery and supporting better respiratory health management.
  • Elastomer for Injectable Primary Packaging Components: AptarGroup's elastomeric components are essential for ensuring the safety, integrity, and effectiveness of injectable medications. These high-quality components play a crucial role in the pharmaceutical packaging industry.
  • Active Material Science Solutions: Expanding beyond traditional dispensing solutions, AptarGroup is also deeply involved in offering active material science solutions. These innovations focus on enhancing product preservation, extending shelf life, and improving the overall consumer experience.
  • Dispensing Pumps, Closures, and Aerosol Valves: AptarGroup’s product range includes a variety of dispensing pumps, closures, and aerosol valves designed for the consumer goods sector. These solutions are tailored to enhance the functionality and user-friendliness of a wide range of products, from personal care items to home cleaning agents.
  • Digital Health Solutions: Recognizing the growing importance of technology in healthcare, AptarGroup offers digital health solutions that leverage the power of digital tools to enhance medication adherence, patient engagement, and overall health outcomes.

Contact Information

Address: 265 Exchange Drive
Phone: 815 477 0424